Home LiteratureArticle Details
PMID: 15115984 Published · ppublish English Journal Article Research Support, U.S. Gov't, P.H.S.

Inhaled nitric oxide decreases pulmonary soluble guanylate cyclase protein levels in 1-month-old lambs.

The Journal of thoracic and cardiovascular surgery ·Vol. 127 ·No. 5 ·2004-05-00 ·Pages 1285-92

Thelitz S, Bekker JM, Ovadia B, Stuart RB, Johengen MJ, Black SM, Fineman JR

Abstract

Inhaled nitric oxide produces potent pulmonary vasodilation by activating soluble guanylate cyclase and increasing smooth muscle cell concentrations of cyclic guanosine monophosphate. However, responses are often nonsustained, and clinically significant increases in pulmonary vascular resistance have been noted on its acute withdrawal. In vitro and in vivo data suggest that inhaled nitric oxide decreases endogenous nitric oxide synthase activity. The effects of inhaled nitric oxide on the downstream mediators of the nitric oxide/cyclic guanosine monophosphate cascade, soluble guanylate cyclase and phosphodiesterase 5, have not been investigated. We sought to determine the effects of inhaled nitric oxide on endogenous cyclic guanosine monophosphate levels, soluble guanylate cyclase, and phosphodiesterase 5 protein levels in the intact lamb. Eleven 1-month-old lambs were mechanically ventilated. In 7 lambs, inhaled nitric oxide (40 ppm) was administered for 24 hours and then acutely withdrawn. Intermittent lung biopsy samples were obtained for cyclic guanosine monophosphate concentrations and soluble guanylate cyclase and phosphodiesterase 5 protein levels (Western blot analysis). Initiation of nitric oxide decreased left pulmonary vascular resistance by 26.2%, and withdrawal rapidly increased pulmonary vascular resistance by 77.8% (P <.05). Tissue cyclic guanosine monophosphate concentrations initially increased during nitric oxide therapy but were not maintained during the 24-hour exposure. In addition, cyclic guanosine monophosphate concentrations rapidly decreased after nitric oxide withdrawal (P <.05). The alpha soluble guanylate cyclase (-45.7%) and beta soluble guanylate cyclase (-48.4%) protein levels decreased during nitric oxide therapy (P <.05), whereas phosphodiesterase 5 proteins levels were unchanged. These data suggest a role for decreased soluble guanylate cyclase and its resulting decrease in cyclic guanosine monophosphate concentrations in the nonsustained response to nitric oxide and the rebound pulmonary hypertension noted on its acute withdrawal. Phosphodiesterase 5 inhibitors may be a useful adjunct therapy during inhaled nitric oxide to preserve cyclic guanosine monophosphate levels and thereby preserve nitric oxide responsiveness and prevent rebound pulmonary hypertension.

MeSH Terms
3',5'-Cyclic-GMP Phosphodiesterases Administration, Inhalation Animals Blotting, Western Cyclic GMP/metabolism Cyclic Nucleotide Phosphodiesterases, Type 5 Guanylate Cyclase/metabolism Hemodynamics/drug effects Lung/enzymology Nitric Oxide/administration & dosage,pharmacology Phosphoric Diester Hydrolases/metabolism Pulmonary Circulation/drug effects Sheep Vascular Resistance/drug effects Vasodilator Agents/administration & dosage,pharmacology
Chemicals
Vasodilator Agents Nitric Oxide Phosphoric Diester Hydrolases 3',5'-Cyclic-GMP Phosphodiesterases Cyclic Nucleotide Phosphodiesterases, Type 5 Guanylate Cyclase Cyclic GMP
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Thelitz Stephan
Department of Cardiothoracic Surgery, University of California, San Francisco 94143-0106, USA.
Bekker Janine M
Ovadia Boaz
Stuart Regan B
Johengen Michael J
Black Stephen M
Fineman Jeffrey R
Article Info
Journal
The Journal of thoracic and cardiovascular surgery
Abbr.
J Thorac Cardiovasc Surg
ISSN
0022-5223
Published
2004-05-00
Pages
1285-92
Language
English
Region
United States
NLM ID
0376343
Subset
IM
Grants
NICHD NIH HHS · HD398110 · United States
NHLBI NIH HHS · HL07061 · United States
NHLBI NIH HHS · HL61284 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]